

Contemporary Treatment of Endometrial Cancer – Clinical Brief #3

References

Tweet 9

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Uterine Neoplasms (v1.2022). Updated November 4, 2021. Accessed March 29, 2022. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

Tweet 10

Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. *N Engl J Med*. 2022;386(5):437-448. doi:10.1056/NEJMoa2108330

Makker V, Taylor MH, Oaknin A, et al. Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab. *The Oncologist*. 2021;26(9):e1599-e1608. doi:10.1002/onco.13883

Tweet 11

Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. *N Engl J Med*. 2022;386(5):437-448. doi:10.1056/NEJMoa2108330

Tweet 12

JEMPERLI (dostarlimab-gxly). Prescribing information. GlaxoSmithKline. Approved 2021. Revised April 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf

KEYTRUDA® (pembrolizumab). Prescribing information. Merck Sharp & Dohme Corp. Approved 2014. Revised March 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf

Tweet 14

LENVIMA® (lenvatinib). Prescribing information. Eisai Inc. Approved 2015. Revised December 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206947s021lbl.pdf

Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. *N Engl J Med*. 2022;386(5):437-448. doi:10.1056/NEJMoa2108330

Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. *J Clin Oncol*. 2020;38(26):2981-2992. doi:10.1200/jco.19.02627

Makker V, Taylor MH, Oaknin A, et al. Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab. *The Oncologist*. 2021;26(9):e1599-e1608. doi:10.1002/onco.13883

Glossary

AE, adverse event
BMI, body mass index
BP, blood pressure
CI, confidence interval
Chemo, chemotherapy
dMMR, deficient mismatch repair
EC, endometrial cancer
HR, hazard ratio
HTN, hypertension
IV, intravenous
LEN, lenvatinib
mDOR, median duration of response
mOS, median overall survival
mPFS, median progression-free survival
MSI-H, microsatellite instability-high
MSS, microsatellite stable
ORR, objective response rate
OS, overall survival
Pembro, pembrolizumab
PFS, progression-free survival
PO, by mouth
pMMR, proficient mismatch repair
Q3W, once every 3 weeks
w/, with